Giuliana Pelicci
Overview
Explore the profile of Giuliana Pelicci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rackles E, Zaccheroni E, Hernandez Lopez P, Faletti S, Del Bene M, DiMeco F, et al.
J Extracell Biol
. 2024 Aug;
3(8):e168.
PMID: 39100684
Circulating cell-free nucleic acids are considered a promising source of biomarkers for diseases and cancer. Liquid biopsy biomarkers for brain tumours represent a major, still unmet, clinical need. In plasma,...
2.
Crestani M, Kakogiannos N, Iori S, Iannelli F, Dini T, Maderna C, et al.
Small Methods
. 2024 May;
8(12):e2400210.
PMID: 38747088
Glioblastomas exhibit remarkable heterogeneity at various levels, including motility modes and mechanoproperties that contribute to tumor resistance and recurrence. In a recent study using gridded micropatterns mimicking the brain vasculature,...
3.
Antona A, Leo G, Favero F, Varalda M, Venetucci J, Faletti S, et al.
Cell Death Discov
. 2023 Jun;
9(1):201.
PMID: 37385999
Among all cancers, colorectal cancer (CRC) is the 3rd most common and the 2nd leading cause of death worldwide. New therapeutic strategies are required to target cancer stem cells (CSCs),...
4.
Lazzarini E, Silvestris D, Benvenuto G, Osti D, Fattore L, Paterra R, et al.
J Neurooncol
. 2023 May;
163(1):47-59.
PMID: 37140883
Purpose: Patient-derived cancer cell lines can be very useful to investigate genetic as well as epigenetic mechanisms of transformation and to test new drugs. In this multi-centric study, we performed...
5.
Ferrarese R, Izzo A, Andrieux G, Lagies S, Bartmuss J, Masilamani A, et al.
Life Sci Alliance
. 2022 Nov;
6(1).
PMID: 36414381
Enhanced fatty acid synthesis is a hallmark of tumors, including glioblastoma. SREBF1/2 regulate the expression of enzymes involved in fatty acid and cholesterol synthesis. Yet, little is known about the...
6.
Faletti S, Osti D, Ceccacci E, Richichi C, Costanza B, Nicosia L, et al.
Sci Transl Med
. 2021 Dec;
13(623):eabf7036.
PMID: 34878824
Glioblastoma (GBM) is a fatal tumor whose aggressiveness, heterogeneity, poor blood-brain barrier penetration, and resistance to therapy highlight the need for new targets and clinical treatments. A step toward clinical...
7.
Del Bene M, Osti D, Faletti S, Beznoussenko G, DiMeco F, Pelicci G
Neuro Oncol
. 2021 Sep;
24(2):184-196.
PMID: 34581817
Glioblastoma (GBM) represents the most aggressive and lethal disease of the central nervous system. Diagnosis is delayed following the occurrence of symptoms, and treatment is based on standardized approaches that...
8.
Monzo P, Crestani M, Chong Y, Ghisleni A, Hennig K, Li Q, et al.
Dev Cell
. 2021 Sep;
56(20):2841-2855.e8.
PMID: 34559979
Glioblastoma are heterogeneous tumors composed of highly invasive and highly proliferative clones. Heterogeneity in invasiveness could emerge from discrete biophysical properties linked to specific molecular expression. We identified clones of...
9.
Fama R, Borroni E, Merlin S, Airoldi C, Pignani S, Cucci A, et al.
Haematologica
. 2020 May;
106(6):1624-1635.
PMID: 32467137
A major challenge in the development of a gene therapy for hemophilia A (HA) is the selection of cell type- or tissue-specific promoters to ensure factor VIII (FVIII) expression without...
10.
Criscuoli M, Ulivieri C, Filippi I, Monaci S, Guerrini G, Crifo B, et al.
J Cell Physiol
. 2020 Jan;
235(11):8058-8070.
PMID: 31944299
Hypoxia occurs in physiological and pathological conditions. T cells experience hypoxia in pathological and physiological conditions as well as in lymphoid organs. Indeed, hypoxia-inducible factor 1α (HIF-1α) affects T cell...